Urinary matrix metalloproteinase-7 (uMMP-7) measured at the time of AKI clinical diagnosis predicted the progression of AKI after cardiac surgery with an AUC of 0.80.
Cohort (n=121)
Yes
Does urinary matrix metalloproteinase-7 (uMMP-7) predict the progression of AKI in adult patients with stage 1 or 2 AKI after cardiac surgery?
uMMP-7 is a novel biomarker that, when measured at the time of AKI diagnosis, can help identify patients at high risk for AKI progression after cardiac surgery.
Effect estimate: AUC 0.80
AIMS: Early detection of patients at high risk for progressive acute kidney injury (AKI) after cardiac surgery remains a major challenge. We aim to evaluate the utility of urinary matrix metalloproteinase-7 (uMMP-7) and other reported biomarkers for predicting AKI progression during postoperative hospital stay. METHODS: We conducted a prospective, multicenter cohort study in 121 adult patients with stage 1 or 2 AKI after cardiac surgery. uMMP-7 and other well-reported biomarkers (uIL-18, uNGAL, and UACR) were measured at time of AKI clinical diagnosis. The primary outcome is the progression of AKI after cardiac surgery, defined as worsening of AKI stage (stage 1 to either stage 2 or stage 3 or from stage 2 to stage 3). RESULTS: g/g after adjusting for clinical risk factors. The performance of uMMP-7 for predicting progressive AKI was good with an AUC of 0.80. The combination of uMMP-7 and IL-18 produces the greatest AUC for predicting progressive AKI. Addition of uMMP-7 to the clinical risk factor model significantly improved risk reclassification for AKI progression. CONCLUSIONS: uMMP-7, measured at time of AKI clinical diagnosis, is a novel biomarker for predicting the progression of AKI after cardiac surgery. Adding uMMP-7 to the clinical risk factor model may be used as a noninvasive approach to identify a subpopulation that is at high risk for progressive AKI after cardiac surgery.
Fan et al. (Tue,) conducted a cohort in Stage 1 or 2 AKI after cardiac surgery (n=121). Urinary matrix metalloproteinase-7 (uMMP-7) vs. Clinical risk factor model was evaluated on Progression of AKI after cardiac surgery, defined as worsening of AKI stage (stage 1 to either stage 2 or stage 3 or from stage 2 to stage 3) (AUC 0.80). Urinary matrix metalloproteinase-7 (uMMP-7) measured at the time of AKI clinical diagnosis predicted the progression of AKI after cardiac surgery with an AUC of 0.80.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: